Document Detail

Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
MedLine Citation:
PMID:  19700173     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Nonmotor symptoms (NMSs) are common in patients with Parkinson disease (PD), but little is known about the burden of the full range of NMSs in de novo PD patients. OBJECTIVES: NMSs in untreated de novo PD patients were evaluated both quantitatively and qualitatively using the Non-Motor Symptoms Assessment Scale (NMSS); the findings were compared to those of control subjects. The effects of dopaminergic treatment on NMSs were also determined. METHODS: NMSs were evaluated in 23 patients with untreated de novo PD and 23 healthy controls. The motor section of the Unified Parkinson Disease Rating Scale (mUPDRS) and the Hoehn and Yahr (HY) stage were also checked in the PD patients. The number of NMSs and the NMSS scores of the PD patients were compared with those of the controls. Three months after the start of dopaminergic medication, 16 PD patients were reevaluated with respect to the NMSS and mUPDRS, and the HY stage. RESULTS: The number of NMSs and the NMSS scores were significantly higher in the PD patients than in the controls. The three most prevalent NMSs among the PD patients were 'nocturia,' 'forget things or events,' and 'restless legs.' In the PD group, the number of NMSs was correlated with the HY stage but not with age, disease duration, or mUPDRS score. Follow-up of 16 patients at 3months after commencing PD medication revealed no changes in either the number of NMSs or the NMSS score, despite improvement in motor symptoms. CONCLUSIONS: Untreated de novo PD patients have more nonmotor problems than controls, and these NMSs are not ameliorated by dopaminergic medication.
Han-Joon Kim; So-Young Park; Yong-Jin Cho; Keun-Sik Hong; Joong-Yang Cho; So-Young Seo; Dong-Ha Lee; Beom S Jeon
Related Documents :
1351273 - Partial dopamine agonist therapy of levodopa-induced dyskinesias.
10442253 - The apolipoprotein e epsilon 4 allele increases the risk of drug-induced hallucinations...
6238643 - Lymphocyte subsets in renal carcinoma--a sequential study using monoclonal antibodies.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-08-22
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  287     ISSN:  1878-5883     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-09     Completed Date:  2010-02-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  200-4     Citation Subset:  IM    
Department of Neurology, Movement Disorder Center, Seoul National University Hospital, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiparkinson Agents / administration & dosage
Benzothiazoles / administration & dosage
Cognition Disorders / diagnosis,  epidemiology
Disability Evaluation
Dopamine Agonists / administration & dosage*
Gastrointestinal Diseases / diagnosis,  epidemiology
Indoles / administration & dosage
Levodopa / administration & dosage
Memory Disorders / diagnosis,  epidemiology*
Middle Aged
Mood Disorders / diagnosis,  epidemiology
Movement Disorders / drug therapy,  physiopathology
Neurologic Examination
Nocturia / diagnosis,  epidemiology*
Outcome Assessment (Health Care)
Parkinson Disease / drug therapy*,  epidemiology*,  physiopathology
Restless Legs Syndrome / diagnosis,  epidemiology*
Treatment Outcome
Reg. No./Substance:
0/Antiparkinson Agents; 0/Benzothiazoles; 0/Dopamine Agonists; 0/Indoles; 0/Levodopa; 104632-26-0/pramipexol; 91374-21-9/ropinirole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heart rate variability in bipolar mania and schizophrenia.
Next Document:  Taxonomic sufficiency in the detection of natural and human-induced changes in marine assemblages: A...